TITLE

Abciximab was more effective than tirofiban in preventing ischemic events in patients having coronary stenting

PUB. DATE
January 2002
SOURCE
ACP Journal Club;Jan/Feb2002, Vol. 136 Issue 1, p5
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Presents an abstract of the study 'Comparison of two Platelet Glycoprotein IIb/IIIb Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events With Percutaneous Coronary Revascularization,' by E. J. Topol, D. J. Moliterno, H. C. Herrmann, et al., published on the June 21, 2002 issue of the 'New England Journal of Medicine.' Comment on the study.
ACCESSION #
8866193

 

Related Articles

  • Orally Active Peptidomimetic RGD Analogs that are Glycoprotein IIb/IIIa Antagonists. Wang, W.; Borchardt, R.T.; Wang, B. // Current Medicinal Chemistry;Apr2000, Vol. 7 Issue 4, p437 

    AbstractPeptidomimetic RGD (Arg-Gly-Asp) analogs, which bind to glycoprotein (GP) IIb/IIIa on the surface of activated platelets, have been shown to inhibit platelet aggregation. Consequently, such RGD analogs can be used for the treatment of unstable angina pectoris and myocardial infarction....

  • Review: Glycoprotein IIb/IIIa inhibitors reduced death or MI in acute coronary syndromes not routinely scheduled for revascularization. Bates, Eric R. // ACP Journal Club;Jul/Aug2002, Vol. 137 Issue 1, p2 

    Presents information on a study that examined the efficacy and safety of glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes not routinely scheduled for early coronary revascularization. Data sources; Study selection; Data extraction; Main results; Conclusion.

  • Abciximab: An Updated Review of its Use in Ischaemic Heart Disease. Foster, R.H.; Wiseman, L.R. // Drugs;Oct1998, Vol. 56 Issue 4, p629 

    Abciximab is a glycoprotein IIb/IIIa receptor antagonist that has proven to be of significant clinical value in improving patient outcome after percutaneous coronary revascularisation. Primarily, the drug inhibits platelet aggregation, but it may also have anticoagulant activity and other...

  • Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. Tricoci, Pierluigi; Huang, Zhen; Held, Claes; Moliterno, David J.; Armstrong, Paul W.; Van de Werf, Frans; White, Harvey D.; Aylward, Philip E.; Wallentin, Lars; Chen, Edmond; Lokhnygina, Yuliya; Pei, Jinglan; Leonardi, Sergio; Rorick, Tyrus L.; Kilian, Ann M.; Jennings, Lisa H.K.; Ambrosio, Giuseppe; Bode, Christoph; Cequier, Angel; Cornel, Jan H. // New England Journal of Medicine;1/5/2012, Vol. 366 Issue 1, p20 

    Background: Vorapaxar is a new oral protease-activated�receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation. Methods: In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes...

  • Drug-eluting Stents. S. Bölükbas; J. Jähne; J. Schirren // Der Chirurg;Jun2009, Vol. 80 Issue 6, p502 

    Zusammenfassung  Die perkutane Koronarintervention (PCI) hat eine besondere Rolle in der Therapie der koronaren Herzerkrankung. „Drug-eluting“ Stents (DES) bedingen eine duale Thrombozytenaggregationshemmung für mindestens ein Jahr. Diese Medikation erschwert planbare und...

  • Blood component utilization in cardiac revascularization in comparison of on-and off pump techniques in a tertiary care hospital of North India. Sonker, A.; Chaudhary, R.; Agarwal, S.; Pandey, S.; Khetan, D. // Asian Journal of Transfusion Science;Jul-Dec2007, Vol. 1 Issue 2, p97 

    Introduction: Cardiac revascularizations on a beating heart avoid the side effects of cardiopulmonary bypass (neurological injury and hemodilution and coagulopathy). We examined peri-operative use of blood components during coronary artery bypass grafting using either on-pump or off-pump...

  • Hypothermia-induced platelet aggregation and cognitive decline in coronary artery bypass surgery: a pilot study. Hall, Matthew W.; Hopkins, Ramona O.; Long, James W.; Mohammad, S. Fazal; Solen, Kenneth A. // Perfusion;May2005, Vol. 20 Issue 3, p157 

    Hypothermia-induced platelet aggregation (HIPA) was previously reported in whole blood exposed to synthetic surfaces at 24° -32°C in one-third of normal subjects tested. Cardiopulmonary bypass, conducted with hypothermia, may lead to such aggregation, resulting in microvascular occlusion...

  • Platelet-larger cell ratio and the risk of periprocedural myocardial infarction after percutaneous coronary revascularization. Verdoia, Monica; Barbieri, Lucia; Schaffer, Alon; Cassetti, Ettore; Marino, Paolo; Bellomo, Giorgio; Sinigaglia, Fabiola; Luca, Giuseppe // Heart & Vessels;Jan2015, Vol. 30 Issue 1, p20 

    Periprocedural myocardial infarction (PMI) represents a frequent complication in patients undergoing percutaneous coronary revascularization. Despite great attention focused on pharmacological prevention of periprocedural damage, very little is known about using biomarkers to potentially predict...

  • Glycoprotein IIb/IIIa Receptor Antagonists in Non-ST Elevation Acute Coronary Syndromes and Percutaneous Revascularisation: A Review of Trial Reports. Kong, D.F.; Califf, R.M. // Drugs;Oct1999, Vol. 58 Issue 4, p609 

    Acute coronary syndromes and percutaneous coronary interventions share a common pathophysiological mechanism of intimal disruption and platelet aggregation. Glycoprotein (GP) IIb/IIIa receptor antagonists, which interrupt the final common pathway of platelet activation and aggregation, have been...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics